Truist Financial Reaffirms “Buy” Rating for Encompass Health (NYSE:EHC)

Encompass Health (NYSE:EHC)‘s stock had its “buy” rating restated by Truist Financial in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $116.00 price target on the stock, up from their prior price target of $108.00. Truist Financial’s price objective suggests a potential upside of 16.68% from the stock’s current price.

Several other research firms have also recently weighed in on EHC. Stephens restated an “overweight” rating and set a $105.00 price target on shares of Encompass Health in a report on Tuesday, August 6th. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. KeyCorp increased their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research report on Tuesday. Royal Bank of Canada lifted their price target on shares of Encompass Health from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Finally, UBS Group increased their price objective on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $107.11.

Encompass Health Trading Down 1.9 %

NYSE:EHC opened at $99.42 on Wednesday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.35. Encompass Health has a one year low of $61.08 and a one year high of $102.36. The company has a market cap of $10.00 billion, a PE ratio of 24.01, a PEG ratio of 1.47 and a beta of 0.88. The firm has a 50-day moving average of $94.33 and a 200-day moving average of $88.69.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same period in the previous year, the company posted $0.86 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, equities research analysts expect that Encompass Health will post 4.27 EPS for the current fiscal year.

Encompass Health announced that its board has initiated a share repurchase plan on Wednesday, July 24th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 5.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of Encompass Health stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the transaction, the chief financial officer now owns 136,227 shares of the company’s stock, valued at $11,761,839.18. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in EHC. UMB Bank n.a. increased its stake in Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after acquiring an additional 252 shares during the last quarter. V Square Quantitative Management LLC increased its position in shares of Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares during the last quarter. Oakworth Capital Inc. purchased a new position in shares of Encompass Health during the 2nd quarter valued at about $40,000. Benjamin F. Edwards & Company Inc. lifted its position in Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after buying an additional 198 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Encompass Health in the second quarter worth approximately $58,000. Institutional investors own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.